About 100 reports

Business Overview Products and Services Immuno-Oncology Platform List of Tables Summary Table A : Global Ovarian Cancer Therapeutic Market, by Cancer Type, Through 2022 Summary Table B : Global Ovarian Cancer Therapeutic Market, by Region, Through 2022 Ta

  • Cancer
  • Ovarian Cancer
  • Therapy
  • World
  • Market Size
  • 2.5 EPIDEMIOLOGICAL FORECAST FOR OVARIAN CANCER (2015-2025)
  • 2.5.3 Age-Standardized Diagnosed Incidence of Ovarian Cancer

EpiCast Report: Ovarian Cancer - Epidemiology Forecast to 2025 Summary Ovarian cancer (International Classification of Diseases, 10th Revision [ICD-10] code C56) and cancer of the fallopian tubes and other uterine adnexa (ICD-10 C57) are leading causes of cancer mortality in women (ACS, 2016; CDC, 2016). Cancer of the...

  • Ovarian Cancer
  • Japan
  • United States
  • World
  • Forecast

Global Ovarian Cancer Epidemiology and Patient Flow Analysis - 2017 ##.

  • Ovarian Cancer
  • France
  • United States
  • World
  • Forecast
  • ANALYSIS BY TYPE OF OVARIAN CANCER
  • Ovarian cancer gene therapy molecules by type of ovarian cancer

This pipeline analysis report provides detailed insights into the clinical trials landscape of the gene therapy for ovarian cancer including molecules at various development stages. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as route of administration...

  • Ovarian Cancer
  • United States
  • Advantagene, Inc.
  • Celsion Corporation
  • Takara Bio Inc.

Ovarian Cancer: Update Bulletin [January 2018] This edition presents key opinion leader (KOL) views on recent developments in the ovarian cancer market.

  • Ovarian Cancer
  • Targeted Therapy
  • Therapy
  • United States
  • Market Competition

Ovarian Cancer Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class, By Major Markets And Segment Forecasts, 2016 - 2022 Chapter ## Research Methodology ##. ##.

  • Cancer
  • Ovarian Cancer
  • Therapy
  • United States
  • Forecast

& nbsp; Most payers however will wait for the ovarian cancer market to mature before they deploy any contracts for preferred products.

  • Ovarian Cancer
  • Therapy
  • European Union
  • United States

Epithelial Ovarian Cancer - Epidemiology Forecast to 2027 ##.

  • Ovarian Cancer
  • France
  • Germany
  • Italy
  • Spain

Ovarian cancer Phase ## Clinical Trials, 2016 ##.

  • Ovarian Cancer
  • France
  • Germany
  • United States
  • Market Size

Epithelial Ovarian Cancer - Market Insight, Epidemiology and Market Forecast - 2027 ##.

  • Cancer
  • Ovarian Cancer
  • Pathology
  • United States
  • Market Shares

Europe Ovarian Cancer Epidemiology and Patient Flow Analysis - 2017 ##.

  • Ovarian Cancer
  • Europe
  • France
  • Germany
  • Forecast
  • BIOMARKERS USED IN OVARIAN CANCER (2017)
  • 4.2.2 Development of Ovarian Cancer Diagnosis Methods and Biomarkers

PARP means poly (adenosine diphosphate [ADP] -ribose) polymerase. It is a family of 17 enzymes that combine several (poly) units of ADP-ribose in a chain (the PAR chain) and transfers them to the target proteins. This helps to restore DNA when it is damaged. DNA can be damaged by many factors, including exposure to...

  • Ovarian Cancer
  • World
  • AbbVie Inc.
  • AstraZeneca PLC
  • Clovis Oncology, Inc.
  • 4.3.5 Ovarian Cancer Testing Market and Forecast
  • GLOBAL - FORECAST FOR OVARIAN CANCER TESTING MARKET (MILLION US$), 2016 - 2021

The molecular diagnostics market is one of the most rapidly growing segments of the in vitro diagnostics industry. Molecular diagnostics is a new class of diagnostic tests that identify molecular and genetic markers for an individual patient. These markers determine potential benefit from a specific therapy or risk of developing a specific...

  • Ovarian Cancer
  • World
  • Forecast
  • bioMerieux S.A.
  • Cepheid

Ovarian cancer Phase ## Clinical Trials, 2016 ##.

  • Ovarian Cancer
  • France
  • Germany
  • Italy
  • Market Size

Ovarian cancer Phase ## Clinical Trials, 2016 ##.

  • Cancer
  • Ovarian Cancer
  • Pathology
  • Japan
  • Market Size

Ovarian cancer Phase ## Clinical Trials, 2016 ##.

  • Cancer
  • Ovarian Cancer
  • Pathology
  • United States
  • Market Size

Ovarian cancer Phase ## Clinical Trials, 2016 ##.

  • Cancer
  • Ovarian Cancer
  • Pathology
  • Italy
  • Market Size

Ovarian cancer Phase ## Clinical Trials, 2016 ##.

  • Cancer
  • Ovarian Cancer
  • Pathology
  • United Kingdom
  • Market Size

Ovarian cancer Phase ## Clinical Trials, 2016 ##.

  • Cancer
  • Ovarian Cancer
  • Pathology
  • Germany
  • Market Size

Ovarian cancer Phase ## Clinical Trials, 2016 ##.

  • Cancer
  • Ovarian Cancer
  • Pathology
  • France
  • Market Size

Ovarian cancer Phase ## Clinical Trials, 2016 ##.

  • Cancer
  • Ovarian Cancer
  • Pathology
  • Spain
  • Market Size
  • Ovarian Cancer Treatment Drugs Sales Volume (million yuan)
  • CHAPTER IV OVARIAN CANCER TREATMENT DRUGS PRODUCTION AND DEMAND

China’s demand for Ovarian Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export,...

  • Ovarian Cancer
  • China
  • Demand
  • Bayer Schering Pharmaceutical Co., Ltd
  • Roche Group

Estrogen signaling is involved in a number of diseases with big market indications such as breast cancer, prostate cancer and osteoporosis.

  • Ovarian Cancer
  • China
  • Demand
  • Bayer Schering Pharmaceutical Co., Ltd
  • Roche Group
  • EPIDEMIOLOGY - OVARIAN CANCER
  • Launch of Lynparza for ovarian cancer

PARP Inhibitors in Oncology Summary Poly (ADP-ribose) polymerase (PARP) enzymes play important roles in the repair of single-strand breaks (SSBs) in DNA.SSBs occur from environmental agents, spontaneous DNA bond disruption, or normal DNA metabolism. PARP1 binds to DNA following SSB and recruits...

  • Ovarian Cancer
  • Targeted Therapy
  • United States
  • AbbVie Inc.
  • Pfizer Inc.
  • Ovarian Cancer Treatment Drugs Sales Volume (million yuan)
  • CHAPTER IV OVARIAN CANCER TREATMENT DRUGS PRODUCTION AND DEMAND

This study focuses on China’s Ovarian Cancer Treatment Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the...

  • Ovarian Cancer
  • China
  • ACON Biotech Co., Ltd
  • Bayer Schering Pharmaceutical Co., Ltd
  • Ltd Jiangsu Hengrui Medicine Co.

Drug Overview: Rubraca

8770 10000 7800

Drug Overview: Rubraca TABLE OF CONTENTS ## Product Profiles ## Rubraca : Prostate cancer ## Rubraca : Ovarian cancer LIST OF FIGURES ## Figure ##: Rubraca for prostate cancer – SWOT analysis ## Figure ##: Datamonitor Healthcare’s drug assessment summary of R

  • Ovarian Cancer
  • Prostate Cancer
  • Therapy
  • European Union
  • United States

Drug Analysis: Rubraca

8770 10000 7800

Drug Analysis: Rubraca Product Profiles Rubraca : Prostate cancer Rubraca : Ovarian cancer LIST OF FIGURES Figure ##: Rubraca for prostate cancer – SWOT analysis Figure ##: Datamonitor Healthcare’s drug assessment summary of Rubraca for prostate

  • Ovarian Cancer
  • Prostate Cancer
  • Therapy
  • European Union
  • United States
  • Canada Incidence of ovarian cancer by 5-yr age cohort, females (000s)
  • Mexico Incidence of ovarian cancer by 5-yr age cohort, females (000s)

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on BRCA1 and BRCA2 mutation in Cancer in 18 Major Markets It has long been established that BRCA1 and BRCA2 (BReast CAncer susceptibility gene) germline mutations confer a higher risk of developing ovarian or breast cancer in women that carry the mutation....

  • Ovarian Cancer
  • East Asia
  • North America
  • South America
  • Western Europe

Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain Dominance Despite New Launches ## Table of Contents ## Table of Contents ## ##. ## List of Tables ## ##. ## List of Figures ## ## Introduction ## ##. ## Disease Pathophysiology ## ##. ##

  • Ovarian Cancer
  • Therapy
  • APAC
  • World
  • Forecast
  • LATEST CLINICAL TRIALS NEWS ON OVARIAN CANCER
  • ADVANCED MALIGNANCY, METASTATIC OVARIAN CANCER, SOLID TUMOR

Ovarian Cancer Global Clinical Trials Review, H1, 2018 Summary GlobalData’s clinical trial report, “Ovarian Cancer Global Clinical Trials Review, H1, 2018" provides an overview of Ovarian Cancer clinical trials scenario.This report provides top line data relating to the clinical trials on Ovarian...

  • Cancer
  • Chemotherapy
  • Clinical Trial
  • Ovarian Cancer
  • World